YU42603A - Laktamska jedinjenja i njihova farmaceutska primena - Google Patents

Laktamska jedinjenja i njihova farmaceutska primena

Info

Publication number
YU42603A
YU42603A YU42603A YUP42603A YU42603A YU 42603 A YU42603 A YU 42603A YU 42603 A YU42603 A YU 42603A YU P42603 A YUP42603 A YU P42603A YU 42603 A YU42603 A YU 42603A
Authority
YU
Yugoslavia
Prior art keywords
diabetic
lactam compounds
pharmaceutical use
glucose
preventives
Prior art date
Application number
YU42603A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Yukio Iino
Takao Ikenoue
Hiroyuki Matsueda
Toshihiro Hatanaka
Ryusuke Hirama
Yoko Masuzawa
Akiyo Yamazaki
Nobuo Kondo
Fumio Ohta
Original Assignee
Ajinomoto Co.Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co.Inc. filed Critical Ajinomoto Co.Inc.
Publication of YU42603A publication Critical patent/YU42603A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
YU42603A 2000-12-01 2001-11-29 Laktamska jedinjenja i njihova farmaceutska primena YU42603A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01

Publications (1)

Publication Number Publication Date
YU42603A true YU42603A (sh) 2006-03-03

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
YU42603A YU42603A (sh) 2000-12-01 2001-11-29 Laktamska jedinjenja i njihova farmaceutska primena

Country Status (26)

Country Link
US (3) US7153850B2 (enExample)
EP (1) EP1346993B1 (enExample)
JP (2) JP3826400B2 (enExample)
KR (1) KR100826818B1 (enExample)
CN (2) CN1269818C (enExample)
AT (1) ATE446297T1 (enExample)
AU (3) AU1850202A (enExample)
BG (1) BG107857A (enExample)
BR (1) BR0115852A (enExample)
CA (1) CA2430124C (enExample)
CZ (1) CZ20031520A3 (enExample)
DE (1) DE60140270D1 (enExample)
ES (1) ES2331299T3 (enExample)
HU (1) HUP0400806A3 (enExample)
IL (1) IL156158A0 (enExample)
MX (1) MXPA03004876A (enExample)
NO (1) NO325401B1 (enExample)
NZ (1) NZ526164A (enExample)
PL (1) PL362835A1 (enExample)
RU (1) RU2287530C2 (enExample)
SK (1) SK6582003A3 (enExample)
TW (1) TWI241302B (enExample)
UA (1) UA76969C2 (enExample)
WO (1) WO2002044180A1 (enExample)
YU (1) YU42603A (enExample)
ZA (1) ZA200304100B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331299T3 (es) * 2000-12-01 2009-12-29 Ajinomoto Co., Inc. Compuestos de lactama y su uso medico.
MXPA05008363A (es) * 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.
CA2544310A1 (en) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
JPWO2005068467A1 (ja) * 2004-01-14 2007-12-27 味の素株式会社 新規縮環化合物
JP2008515939A (ja) * 2004-10-13 2008-05-15 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄｋ２及び血管形成の阻害剤として、及び乳癌、結腸癌及び前立腺癌の治療に有用な２置換ピラゾロベンゾジアゼピン
NZ563131A (en) * 2005-04-28 2010-09-30 Ajinomoto Kk Tricyclic lactam compound as a hypoglycemic agent
EP2157092A4 (en) 2007-04-11 2011-04-13 Ajinomoto Kk Remedy for diabetes
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
RU2017126027A (ru) * 2014-12-22 2019-01-24 ЕА Фарма Ко., Лтд. Лекарственное средство для лечения расстройств эпителия роговицы
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
WO2020151671A1 (en) * 2019-01-23 2020-07-30 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
NZ502448A (en) 1997-07-30 2002-12-20 Wyeth Corp Tricyclic vasopressin agonists and medicaments containing these compounds
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
ES2331299T3 (es) * 2000-12-01 2009-12-29 Ajinomoto Co., Inc. Compuestos de lactama y su uso medico.
MXPA05008363A (es) 2003-02-07 2005-12-06 Ajinomoto Kk Agentes terapeuticos para diabetes.

Also Published As

Publication number Publication date
RU2287530C2 (ru) 2006-11-20
PL362835A1 (en) 2004-11-02
AU2006241377A1 (en) 2006-12-14
US7326701B2 (en) 2008-02-05
US7153850B2 (en) 2006-12-26
CA2430124C (en) 2011-01-11
JP2006213732A (ja) 2006-08-17
ZA200304100B (en) 2004-08-22
NO20032439D0 (no) 2003-05-28
US7632830B2 (en) 2009-12-15
US20040048847A1 (en) 2004-03-11
JP3826400B2 (ja) 2006-09-27
ATE446297T1 (de) 2009-11-15
CN1269818C (zh) 2006-08-16
CN100577651C (zh) 2010-01-06
AU2006241377B2 (en) 2009-01-08
US20060189597A1 (en) 2006-08-24
AU2002218502B2 (en) 2006-09-21
BR0115852A (pt) 2003-12-23
IL156158A0 (en) 2003-12-23
EP1346993A1 (en) 2003-09-24
KR100826818B1 (ko) 2008-05-02
CA2430124A1 (en) 2002-06-06
US20080096862A1 (en) 2008-04-24
JPWO2002044180A1 (ja) 2004-04-02
NO20032439L (no) 2003-07-18
SK6582003A3 (en) 2003-09-11
JP4505753B2 (ja) 2010-07-21
MXPA03004876A (es) 2004-01-27
UA76969C2 (en) 2006-10-16
ES2331299T3 (es) 2009-12-29
DE60140270D1 (de) 2009-12-03
CZ20031520A3 (cs) 2003-10-15
EP1346993B1 (en) 2009-10-21
CN1487940A (zh) 2004-04-07
KR20030051893A (ko) 2003-06-25
EP1346993A4 (en) 2005-12-21
AU1850202A (en) 2002-06-11
NZ526164A (en) 2004-09-24
HUP0400806A3 (en) 2007-11-28
HUP0400806A2 (hu) 2004-07-28
CN1911915A (zh) 2007-02-14
NO325401B1 (no) 2008-04-21
WO2002044180A1 (en) 2002-06-06
TWI241302B (en) 2005-10-11
BG107857A (bg) 2004-06-30

Similar Documents

Publication Publication Date Title
YU42603A (sh) Laktamska jedinjenja i njihova farmaceutska primena
MXPA03007712A (es) Sales farmaceuticas.
IL138767A0 (en) Anticancer compositions
CA2327973A1 (en) Storage system for powdered pharmaceuticals, and inhaler equipped with this system
WO2002007712A3 (en) Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
WO2004054542A3 (en) Oral drug delivery system comprising high viscosity liquid carrier materials
MX2010004222A (es) Formulaciones solidas de compuestos cristalinos.
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
WO2007081949A3 (en) Small-volume oral transmucosal dosage forms
SI1169024T1 (sl) Predzelatinirani skrob v formulaciji s kontroliranim sproscanjem
EP1295609A4 (en) MEDICINES WITH MIXED ACTIVE SUBSTANCES
WO2007079082A3 (en) Gastric release pulse system for drug delivery
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
WO2001082897A3 (en) Liposome drug delivery
WO2005007137A8 (de) Ambroxolhaltige tabletten
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
EP1452176A4 (en) AGENTS FOR IMPROVING THE STATE OF RESISTANCE OF INSULIN
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
WO2004026319A3 (en) Pharmaceutical compositions increasing camp useful for the treatment of cancers
WO2005110358A3 (de) Filmförmiges, oral zu verabreichendes arzneimittel, enthaltend estriol
SG152285A1 (en) Solid pharmaceutical formulation
WO2001037818A3 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
WO2005020968A3 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
ZA200202426B (en) Pyrimidine derivatives, process for preparing the derivatives and drugs containing the same as the active ingredient.